From the macro perspective, the present study indicates that METTL3 may be a potential therapeutic target in NSCLC, and reveals that the METTL3/ABCC2 axis serves as a critical regulator in PTX- and CBP-resistant NSCLCs. This evidence concerns the gene ABCC2 and non-small cell lung carcinoma.